Page last updated: 2024-11-11

papaveroline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

papaveroline: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5459346
CHEMBL ID351585
CHEBI ID135171
SCHEMBL ID564044
MeSH IDM0057071

Synonyms (38)

Synonym
nsc-99799
574-77-6
NSC99799 ,
NCI60_042244
23740-74-1
1-(3,4-dihydroxybenzyl)-6,7-isoquinolinediol
papaveroline, hydrobromide
1-[(3,4-dihydroxyphenyl)methyl]isoquinoline-6,7-diol
NCGC00014041
NCI99799
1-(3,4-dihydroxybenzyl)isoquinoline-6,7-diol
papaveroline
papaverolina [inn-spanish]
papaverolinum [inn-latin]
einecs 209-374-1
papaveroline [inn:ban]
NCISTRUC1_001453
NCISTRUC2_001040
NCGC00097150-01
CHEBI:135171
CHEMBL351585
papaverolinum
unii-a0cr5j8x17
papaverolina
a0cr5j8x17 ,
nsc 99799
CCG-37436
NCGC00014041-02
papaveroline [mart.]
papaveroline [who-dd]
papaveroline [inn]
SCHEMBL564044
MXQKCNCLQIHHJA-UHFFFAOYSA-N
6,7-isoquinolinediol, 1-[(3,4-dihydroxyphenyl)methyl]-
papaverolin
DTXSID50972889
1-[(3,4-dihydroxyphenyl)methyl]-7-hydroxyisoquinolin-6(2h)-one
Q27273466
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
isoquinolinesA class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency2.82140.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency2.82140.025120.237639.8107AID886; AID893
15-lipoxygenase, partialHomo sapiens (human)Potency3.98110.012610.691788.5700AID887
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency1.25890.00207.533739.8107AID891
cytochrome P450 2C9 precursorHomo sapiens (human)Potency5.01190.00636.904339.8107AID883
caspase-1 isoform alpha precursorHomo sapiens (human)Potency3.98110.000311.448431.6228AID900
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency5.01190.00638.235039.8107AID883
Caspase-7Homo sapiens (human)Potency3.16233.981118.585631.6228AID889
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
proteolysisCaspase-7Homo sapiens (human)
apoptotic processCaspase-7Homo sapiens (human)
heart developmentCaspase-7Homo sapiens (human)
response to UVCaspase-7Homo sapiens (human)
protein processingCaspase-7Homo sapiens (human)
protein catabolic processCaspase-7Homo sapiens (human)
defense response to bacteriumCaspase-7Homo sapiens (human)
fibroblast apoptotic processCaspase-7Homo sapiens (human)
striated muscle cell differentiationCaspase-7Homo sapiens (human)
neuron apoptotic processCaspase-7Homo sapiens (human)
protein maturationCaspase-7Homo sapiens (human)
lymphocyte apoptotic processCaspase-7Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-7Homo sapiens (human)
cellular response to staurosporineCaspase-7Homo sapiens (human)
execution phase of apoptosisCaspase-7Homo sapiens (human)
positive regulation of plasma membrane repairCaspase-7Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
RNA bindingCaspase-7Homo sapiens (human)
aspartic-type endopeptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-7Homo sapiens (human)
protein bindingCaspase-7Homo sapiens (human)
peptidase activityCaspase-7Homo sapiens (human)
cysteine-type peptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in execution phase of apoptosisCaspase-7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
extracellular spaceCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
cytoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
nucleoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID63018Inhibition of [3H]Spiroperidol binding to dopamine receptor from rat striatum membranes; Inactive1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Mammalian alkaloids. 8. Synthesis and biological effects of tetrahydropapaveroline related 1-benzyltetrahydroisoquinolines.
AID33139Inhibition of [3H]WB-4101 binding to alpha adrenergic receptor from rat cerebral cortical membranes; Inactive1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Mammalian alkaloids. 8. Synthesis and biological effects of tetrahydropapaveroline related 1-benzyltetrahydroisoquinolines.
AID41753Inhibition of [3H]dihydroalprenolol binding to Beta adrenergic receptor from rat cerebral cortical membranes1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Mammalian alkaloids. 8. Synthesis and biological effects of tetrahydropapaveroline related 1-benzyltetrahydroisoquinolines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (87.50)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.09 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (12.50%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]